The American surgeon · 2020
Extracorporeal Membrane Oxygenation for COVID-19-Associated Multisystem Inflammatory Syndrome in a 5-year-old.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schwartz Stephanie P, Walker Tracie C, Kihlstrom Margaret, Isani Mubina, Smith Melissa M, Smith Rebecca L, McLean Sean E, Clement Katherine C, Phillips Michael R
Аннотация
Severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) is associated with multisystem inflammatory syndrome in children (MIS-C) that ranges from mild symptoms to cardiopulmonary collapse. A 5-year-old girl presented with shock and a rapid decline in left ventricular function requiring intubation. SARS-CoV-2 was diagnosed by viral Polymerase Chain Reaction (PCR), and she received remdesivir and COVID-19 convalescent plasma. Initial echocardiogram (ECHO) demonstrated low normal left ventricular function and mild left anterior descending coronary artery dilation. She remained hypotensive, despite high-dose epinephrine and norepinephrine infusions as well as stress-dose hydrocortisone. Admission SARS-CoV-2 IgG assay was positive, meeting the criteria for MIS-C. An ECHO 9 hours after admission demonstrated a severe decline in left ventricular function. Due to severe cardiogenic shock, she was cannulated for venoarterial extracorporeal support (ECMO). During her ECMO course, she was treated with remdesivir, intravenous methylprednisolone, intravenous immunoglobulin, and anakinra. She was decannulated on ECMO day 7, extubated the following day, and discharged home 2 weeks later without respiratory or cardiac support. The use of ECMO for cardiopulmonary support for pediatric patients with MIS-C is feasible and should be considered early as part of the treatment algorithm for patients with severe cardiopulmonary dysfunction.
Предметные рубрики MeSH
Adenosine MonophosphateAdrenergic alpha-AgonistsAlanineAnti-Inflammatory AgentsAntiviral AgentsCOVID-19Child, PreschoolEpinephrineExtracorporeal Membrane OxygenationFemaleHumansHypotensionImmunization, PassiveImmunoglobulins, IntravenousInterleukin 1 Receptor Antagonist ProteinMethylprednisoloneNorepinephrineShock, CardiogenicSystemic Inflammatory Response SyndromeCOVID-19 SerotherapyCOVID-19 Drug Treatment